Readystate Asset Management LP lifted its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 97.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 169,819 shares of the company's stock after buying an additional 83,700 shares during the quarter. Readystate Asset Management LP owned approximately 0.46% of iTeos Therapeutics worth $1,734,000 as of its most recent SEC filing.
A number of other hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of iTeos Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,500,602 shares of the company's stock worth $20,468,000 after buying an additional 9,660 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of iTeos Therapeutics by 14.8% in the second quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company's stock worth $13,481,000 after buying an additional 117,159 shares during the last quarter. Candriam S.C.A. purchased a new stake in shares of iTeos Therapeutics in the second quarter worth about $7,558,000. Algert Global LLC boosted its stake in shares of iTeos Therapeutics by 92.0% in the third quarter. Algert Global LLC now owns 256,139 shares of the company's stock worth $2,615,000 after buying an additional 122,730 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of iTeos Therapeutics by 3.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 222,135 shares of the company's stock worth $2,268,000 after buying an additional 8,397 shares during the last quarter. Hedge funds and other institutional investors own 97.16% of the company's stock.
Insider Buying and Selling at iTeos Therapeutics
In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction on Tuesday, November 19th. The shares were bought at an average price of $7.73 per share, for a total transaction of $38,650.00. Following the completion of the transaction, the chief financial officer now directly owns 65,429 shares of the company's stock, valued at $505,766.17. This trade represents a 8.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 12.50% of the company's stock.
iTeos Therapeutics Stock Down 1.3 %
Shares of NASDAQ ITOS traded down $0.11 during midday trading on Thursday, hitting $8.08. The stock had a trading volume of 105,376 shares, compared to its average volume of 443,815. iTeos Therapeutics, Inc. has a 1 year low of $7.54 and a 1 year high of $18.75. The company has a market capitalization of $295.16 million, a PE ratio of -2.60 and a beta of 1.37. The stock has a 50 day simple moving average of $9.01 and a 200-day simple moving average of $13.42.
iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.13. As a group, analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have issued reports on ITOS. Wells Fargo & Company began coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $31.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered their price target on iTeos Therapeutics from $27.00 to $24.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. Finally, Wedbush reiterated an "outperform" rating and set a $25.00 price target on shares of iTeos Therapeutics in a research report on Tuesday, November 12th.
Check Out Our Latest Research Report on ITOS
iTeos Therapeutics Profile
(
Free Report)
Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.
Featured Stories
Before you consider iTeos Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.
While iTeos Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
